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Human immunodeficiency virus type 1 (HIV-1) evolution under chemotherapeutic selection pressure in vivo involves a
complex interplay between an increasing magnitude of drug resistance and changes in viral replicative capacity. To examine
the replicative fitness of HIV-1 mutants with single, drug-selected substitutions in protease (PR), we constructed virus that
contained the most common mutations in indinavir-selected clinical isolates, PR M46I and V82T, and the most common
polymorphic change in drug-naı¨ve patients, PR L63P. These mutants were competed in vitro in the absence of drug against
the otherwise isogenic WT virus (NL4-3). Phenotypic drug susceptibility was determined with a recombinant virus assay
using a single cycle of virus growth. PR M46I and L63P were as fit as WT. However, PR V82T was out-competed by WT. None
of these mutants had appreciable phenotypic resistance to any of the protease inhibitors, including indinavir. The PRV82T
mutant was hypersusceptible to saquinavir. Thus, the impaired fitness of the V82T single mutant is consistent with its low
frequency in protease inhibitor-naı¨ve patients. The similar fitness of WT (NL4-3), L63P, and M46I is consistent with the
common occurrence of L63P in the absence of protease inhibitor-selection pressure, but not with the rare detection of M46I
in drug-naı¨ve patients. © 2000 Academic PressKey Words: HIV-1 drug resistance; protease inhibitors; viral replicative fitness; indinavir.INTRODUCTION
The emergence of drug-resistant HIV-1 is an important
limitation of antiretroviral therapy (Hirsch et al., 1998). Re-
sistance mutations are not yet common in drug-naı¨ve pa-
tients, but transmission of protease inhibitor (PI)-resistant
virus occurs (Boden et al., 1999; Hecht et al., 1998; Little et
al., 1999; Yerly et al., 1999). Understanding the effects of
resistance mutations on replicative fitness in the absence
of drug may help to predict which, if any, may be more likely
to persist in untreated patients, including after transmis-
sion. Relatively less fitness favors out-competition by WT in
the absence of drug (Coffin, 1996). Many resistance muta-
tions that are initially selected during drug failure have been
shown to cause impaired fitness (Ho et al., 1994; Martinez-
Picado et al., 1999a; Nijhuis et al., 1999). However, some
multiple mutational patterns are as fit as, or fitter than, wild
type (Caliendo et al., 1996; Kosalaraksa et al., 1998; Nijhuis
et al., 1999).
The relative fitness of PI-resistant mutants has also been
hypothesized to correlate with PI cross-resistance, defined
as decreased susceptibility to several PIs. In an earlier
study, broadly cross-resistant viruses with four or five of the
mutations L10R, M46I, L63P, V82T, and I84V had fitness
equivalent to WT (Martinez-Picado et al., 1999a). Single
mutants initially selected by nelfinavir and saquinavir,
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318which are not cross-resistant to other PIs, were not as fit as
WT in vitro (Martinez-Picado et al., 1999a). Mutants with
only single mutations selected by indinavir were also of
interest to study with regard to the hypothesis that less-fit
viruses would not be cross-resistant.
Detectable phenotypic resistance to indinavir and cross-
resistance with other inhibitors has been reported only with
multiple (three or more) mutations in HIV protease (Condra
et al., 1995; Molla et al., 1996). Codons 46 and 82 are the
most common sites of mutations selected in vivo by indi-
navir (Condra et al., 1996). However, these mutants are
rarely seen in isolation without additional mutations and are
not seen in PI-naı¨ve patients. A mutation in either codon 46
or codon 82 can be the initial mutation selected by indinavir.
The single mutants M46I and V82T did not confer indinavir
resistance or cross-resistance (Condra et al., 1995), by the
use of an assay different from methods now available to
clinicians (Hertogs et al., 1998; Parkin et al., 1999). L63P
does not confer phenotypic resistance to any PI and is
common in PI-naı¨ve patients (Condra et al., 1996; Kozal et
al., 1996). Our goal was to examine the fitness of the single
protease mutant viruses M46I, L63P, and V82T, relative to
WT by in vitro growth competition experiments in the ab-
sence of PIs. We hypothesized that M46I and V82T single
mutants would be less fit than WT, and that the L63P mutant
would be as fit as WT.
RESULTS
Viral replicative fitness of PR mutants M46I, L63P, and
V82T was determined using clonal genotypic analysis of
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319FITNESS OF HIV-1 MUTANTSmixed competitive cultures. The M46I and L63P mutant
viruses each replicated as well as WT (Fig. 1). In mixed
infections starting with 75% M46I or L63P mutant and
25% WT, the proportion of mutant virus did not change
with respect to WT over 21 days.
The V82T protease mutant virus replicated less well
than WT virus in the absence of drugs (Fig. 1). A mixed
infection starting with 75% V82T mutant and 25% WT
virus showed a sharp decrease in the proportion of V82T
shortly after infection, which was sustained throughout
the experiment. This decrease in the proportion of V82T,
and increase in WT, between Days 0 and 7 was statisti-
cally significant (P , 0.005). Sequencing of the V82T
mutant clones from the end of the competition did not
identify any other mutation in these clones in either the
protease coding region or the p7/p1 or p1/p6 cleavage
sites in Pr55gag. In the culture infected only with the V82T
mutant virus, sequences of 20 clones from Day 21
showed no reversion of mutant protease codon 82 (ATC
encoding threonine) to WT (ACC encoding valine).
Susceptibility to indinavir, ritonavir, nelfinavir, and sa-
quinavir was retained by M46I and L63P mutants based
on both IC95s (not shown) and IC50s (Table 1). The IC95
data suggested that the V82T mutant had minimally de-
creased susceptibility only to ritonavir (3.5- and 2.6-fold
increase in IC95 relative to NL4-3, in duplicate assays).
However, ritonavir IC50s of PR V82T (1.9-fold change
from WT in each of two duplicate assays) did not meet
FIG. 1. Determination of the relative replication efficiencies of the wi
at 1 represents fitness equivalent to the WT virus HIV-1NL4-3. Vector arrow
Each of the three protease mutants (M46I, L63P, and V82T) was mix
mutant/25% WT. Ratios of mutant and WT were quantified every 3 or 4
Day 21 were WT.criteria for resistance, .2.5-fold change in IC50 relativeto WT, which are based on the reproducibility of this
assay (Little et al., 1999; Parkin et al., 1999). None of the
utants was resistant to any of the tested PIs, based on
C50s (Table 1). Based on the criteria for hypersuscepti-
ility used for clinical result reporting (,0.4-fold change
rom WT IC50) (Parkin et al., 1999), PR V82T was not
ypersusceptible to indinavir or nelfinavir, but was hy-
ersusceptible to saquinavir (0.2-fold; 0.2-fold of WT IC50
n duplicate assays) (Table 1).
and mutant viruses in competition in MT2 cells. Horizontal dotted line
changes in mutant/WT protease ratios during passages in cell culture.
h WT in independent competition cultures at a starting ratio of 75%
uring the experiment. For the V82T mutant, all 20 clones examined at
TABLE 1
Drug Susceptibility Phenotypes of Molecular Clones
to a Panel of HIV-1 Protease Inhibitors
50% inhibitory concentrations (nM)a
(fold increase in resistance) b
Virus clones Indinavir Nelfinavir Ritonavir Saquinavir
WT (NL4-3) 7.3 4.1 17.3 3.4
M46I 4.8 3.1 11.2 1.8
(0.7) (0.8) (0.7) (0.5)
L63P 7.7 5.0 16.6 3.1
(1.0) (1.2) (1.0) (0.9)
V82T 4.3 1.9 32.1 0.6
(0.6) (0.5) (1.9) (0.2)
a The resistance of each clone to all four protease inhibitors was
etermined by a recombinant virus assay in duplicate (Parkin et al.,
999).
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PR V82T is selected as a primary resistance mutation
uring therapy with indinavir or ritonavir (Condra et al.,
995; Molla et al., 1996). This amino acid directly inter-
cts with these inhibitors. The results of this study sup-
ort the hypothesis that V82T is rarely seen in the ab-
ence of drug selection pressure because it impairs
eplicative fitness relative to the WT virus. The proportion
f V82T decreased significantly by Day 7 of the compet-
tive culture, which was not the result of genetic rever-
ion. V82T mutant was approximately 27% less fit than
T in the absence of drug based on the selection coef-
icient determined from culture Day 10 (Nagylaki, 1992).
he range of values determined from changes between
aseline and each of the four time points in culture was
9–29%, with a standard error of 2.1%. This is unlikely to
e an artifact related to limited availability of target cells
ecause cell viability was maintained in these cultures in
dynamic range of 0.3 to 3 3 106 cells/ml. No additional,
potentially compensatory mutations developed within
the protease coding region or in the Pr160gag-pol cleavage
sites p7/p1, p1/p6, p6*/PR, and PR/RT. Hypersusceptibil-
ity of PR V82T to saquinavir was noted for the first time in
this report. It may be another factor associated with the
rarity of this particular substitution in codon 82 during
saquinavir failure. None of the 81 isolates from patients
treated with saquinavir as their only PI had V82T, al-
though V82A or -I was rarely seen (Shafer et al., 1999).
Unlike V82T, L63P is commonly seen in PI-naı¨ve pa-
tients. It does not directly interact with any inhibitor and
it is generally considered a natural polymorphism (Kozal
et al., 1996). Our results show that L63P is as fit as WT in
the absence of drug. This is consistent with a previous
comparison of replication kinetics in independent cul-
tures (Markowitz et al., 1995) and the similar frequency of
63P and 63L in PI-naı¨ve patients (Kozal et al., 1996).
These data cannot exclude a small difference from WT.
However, sampling 20 clones at each of four time points
yields a 98.3% probability of detecting a 5% difference
between the competing variants. This calculation as-
sumes a binomial distribution, and that the probability of
detecting a 1-in-20 clone difference at one time point is
independent of this probability at another time point.
The M46I mutation participates in hydrophobic inter-
actions on the solvent-exposed face of the flap domain of
the protease (Shao et al., 1997). It is considered a pri-
mary resistance mutation selected during indinavir fail-
ure and is frequently associated with indinavir-selected
mutations in position 82 (Condra et al., 1995, 1996).
Although a single M46I mutant retains suceptibility to all
current protease inhibitors (Table 1), this mutation can
further decrease susceptibility to ritonavir, nelfinavir, or
amprenavir when it is combined with other active site
resistance mutations (De Pasquale et al., 1998; Molla et
al., 1996; Patick et al., 1998). M46I is rare in PI-naı¨vepatients, with an incidence ranging from 0 to 3% (Kozal et
al., 1996; Lech et al., 1996; Roberts et al., 1998). However,
it has been frequently selected during in vitro passage in
several different PIs (Carrillo et al., 1998; Ho et al., 1994;
Markowitz et al., 1995; Tisdale et al., 1995). Based on the
low frequency of this mutation in drug-naı¨ve patients, we
hypothesized that it would impair replicative fitness rel-
ative to WT. However, the results of competitive cultures
in this study show that M46I is as fit as the WT virus, as
did a different methodology (Ho et al., 1994). Other re-
ports that M46I mutant enzyme had reduced proteolytic
efficiency (Gulnik et al., 1995; Pazhanisamy et al., 1996)
may differ because of the particular protease cleavage
site substrates used for the biochemical analyses. One
possible explanation why M46I is not a common poly-
morphism in drug-naı¨ve patient isolates is that it may
confer some relative impairment in fitness in genetic
backgrounds different from that of NL4-3. Since M46I is
as fit as WT in at least some genetic backgrounds, as
documented here, it may be likely to persist in the ab-
sence of protease inhibitor-selection pressure after
transmission from a patient failing a PI more often than
mutants with impaired fitness in vitro.
In an earlier report, we hypothesized that less-fit re-
sistant mutants would not have broad cross-resistance
based on analyses of nelfinavir- and saquinavir-selected
mutants (Martinez-Picado et al., 1999a). In that study,
multiply substituted mutants selected during indinavir
failure were both as fit as wild type and broadly cross-
resistant. The present results with M46I add the infor-
mation that fitness equivalent to WT in the absence of
drug is not sufficient to confer resistance, or cross-
resistance, to drug-selected mutants. Outgrowth of viral
variants in vivo in the presence of drug represents a
combination of both drug susceptibility and growth kinet-
ics in the presence of varying amounts of drug over the
course of the dosing interval. Therefore, increased un-
derstanding of all these factors may help to improve
treatment strategies against resistant HIV.
MATERIALS AND METHODS
PR M46I and V82T mutants were constructed in a wild
type HIV-1NL4-3 background (Adachi et al., 1986) and pro-
vided by Condra et al. (1995). The L63P mutant was
constructed by site-directed mutagenesis using recom-
binant PCR (Martinez-Picado et al., 1999a,b). Virus stocks
were generated by one passage in peripheral blood
mononuclear cells (PBMCs) stimulated with phytohe-
magglutinin (PHA) and interleukin-2 (IL-2) (Martinez-
Picado et al., 1999a).
Growth competition assays were performed in MT2
cells in the absence of drug and using RPMI 1640 (Cell-
gro) supplemented with 10% fetal calf serum (Sigma, St.
Louis, MO), 2 mM L-glutamine (Cellgro, Mediatech,
Washington, D.C.), 10 mM HEPES buffer (Cellgro), and 50
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321FITNESS OF HIV-1 MUTANTSmg of penicillin/ml and 50 mg of streptomycin/ml (both
rom Cellgro). Infections were initiated with unequal
mounts of two competing viral variants, typically 25 and
5%, respectively, based on virus infectivity titrations in
T2 cells. A 2-ml inoculum of 12,000 TCID50 was made
p of a mixture (3000 and 9000 TCID50) of each viral
ariant. Two 1-ml aliquots were adsorbed to 6 3 106 cells
ach (m.o.i. 5 0.001) for 1 h at 37°C. Subsequently, cells
ere pooled, centrifuged, washed with cold phosphate-
uffered saline (PBS), resuspended in medium at a final
oncentration of 106 cells/ml, and incubated at 37°C.
otal and viable cells were counted and cultures fed with
edium every 3 or 4 days. Every 7 days supernatant
luids were collected and diluted (appropriately for each
irus, up to 1:100), and 1 ml was used to infect 6 3 106
fresh MT2 cells for 1 h at 37°C. Then, cells were incu-
bated at the same concentration and conditions as de-
scribed earlier. Dilutions were chosen for each mu-
tant/WT competition passage to maintain the number of
viable cells between 0.3 and 3.0 3 106, thereby repro-
ducing similar virus-to-uninfected cell ratios as in the
initial passage. Aliquots (2 ml) containing cells were
removed from cultures at Days 4, 7, 10, 14, 17, and 21 and
centrifuged, and total infected cell DNA was extracted
(Puregene; Gentra, Minneapolis, MN). MT-2 cells were
also separately infected with mutants in the absence of
WT virus to evaluate reversion.
Three independent 35-cycle PCRs of each infected cell
lysate using primers ApaI988UDG and Sse2835UDG
(Martinez-Picado et al., 1999a) were pooled to minimize
possible biased amplification and cloned into pAMP1
(Clone-Amp; Gibco-BRL, Rockville, MD). Recombinant
plasmids were purified from ampicillin-resistant E. coli
colonies (Qiawell; Qiagen, Chatsworth, CA). Twenty plas-
mids were used per time point to determine the propor-
tion of each virus in the mixed competitive cultures.
Genotyping was performed on 10 mg of cloned PCR
roduct plasmid DNA using the HIV-1 site-specific se-
uencing (HIV-SSS) method (Martinez-Picado et al.,
997). Relative fitness was plotted as previously de-
cribed (Holland et al., 1991). The statistical significance
f differences between the proportion of the two com-
eting viruses at baseline and a later time point was
etermined using Fisher’s exact test. A drug susceptibil-
ty test was performed by recombinant virus assay as
reviously described (Hecht et al., 1998; Parkin et al.,
999).
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